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CASE REPORT
Epidermal Cysts in a Tacrolimus Treated Renal 
Transplant Recipient
In Su Ahn, M.D., Bo Young Chung, M.D., Soo Ick Cho, M.D., Hye One Kim, M.D., 
Chun Wook Park, M.D., Cheol Heon Lee, M.D.
Department of Dermatology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea
Tacrolimus, a calcineurin inhibitor, formerly also known as 
FK506, is a macrolactam drug isolated from Streptomyces 
tsukubaensis. Its mode of action closely parallels the action 
of cyclosprorin A (CsA) and can be used for the treatment of 
inflammatory and autoimmune skin diseases in which 
systemic CsA has proved effective against psoriasis, 
pyoderma gangrenosum, atopic dermatitis, lupus erythe-
matosus and graft versus host disease (GVHD). Although 
several cases of epidermal cysts have been reported in 
patients using cyclosporine and other immunosuppressants 
after organ transplantation; such types of cases have yet not 
been reported after administration of tacrolimus. However, 
we report herein a case of presence of multiple, various sized 
epidermal cysts in a renal transplant recipient receiving 
tacrolimus. (Ann Dermatol 23(S2) S182∼S184, 2011)
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INTRODUCTION
Epidermal cyst is a keratin-filled lesion lined by epidermis. 
It is found most commonly in both male and female adults 
and is presented as single or multiple, intradermal or 
subcutaneous masses
1. This cyst is most commonly the 
result of plugged pilosebaceous units and can also be 
caused by the traumatic implantation of epidermal cells or 
by the proliferation of variable epidermal remnants
2. 
Recently, human papillomavirus (HPV) type 57 and 60 
DNAs have been regarded as etiological factors
1,2. Immu-
nomodulatory drugs, such as cyclosporine or tacrolimus 
are mainly used as immunosuppressants in organ trans-
plantation recipients. They have recently been in the 
spotlight as treatment options for psoriasis, atopic der-
matitis, alopecia areata and other dermatologic diseases. 
Tacrolimus, formerly known as FK506, is a macrolactam 
drug isolated from Streptomyces tsukubaensis
1. Although 
tacrolimus has no structural homology to cyclosporine A 
(CsA), its mode of action closely parallels CsA, and it 
exerts similar in vitro effects at concentrations of 100 
times lower than those of CsA
3. Tacrolimus affects 
numerous aspects of cellular physiology, mainly alteration 
of gene expression in target cells. In particular, inter-
leukin-(IL) 2 gene expression in CD4＋ T-helper lympho-
cytes is inhibited by tacrolimus
4. Although several cases of 
epidermal cysts have been reported in patients using 
cyclosporine and other immunosuppressants after organ 
transplantation, such types of cases have yet not been 
reported after administration of tacrolimus
2,3,5. We report a 
case of presence of multiple, various sized epidermal cysts Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
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Fig. 1. Multiple scattered 0.5∼3 cm sized nodules and tumors
on the back.
in a renal transplant recipient receiving tacrolimus.
CASE REPORT
A 44-year-old male patient was presented with a 1 year 
history of presence of multiple (＞100) cystic masses of 
varying sizes on his neck, back and buttocks. There was 
no definite family history of presence of multiple masses 
on the skin. Oral tacrolimus was administered at an initial 
dose of 10 mg/day and was decreased to a maintenance 
dose of 4 mg/day during the first 6 months of transplan-
tation. Oral steroid (an initial dose of 60 mg/day) was 
tapered and discontinued after 3 months of transplan-
tation. No steroids were administered over the past 4 
years. After 3 years of operation, more than 100 nodules 
and tumors (0.5∼3 cm diameter) occurred on his back 
and neck. They increased in size and number, and some 
of the cysts were infected (Fig. 1). After an excisional 
biopsy, there were neither new lesions nor changes in 
previous skin lesions, such as partial response or 
progression. In the meantime, the patient continued to 
take a low oral dose of tacrolimus (4 mg/day).
DISCUSSION
The frequency of organ transplantation has been rapidly 
increasing in recent years. Accordingly, the use of 
immunosuppressants has risen dramatically. There are 
several kinds of immunosuppressants: calcineurin inhi-
bitors (cyclosporine, tacrolimus and pimecrolimus) in the 
macrolactam group and rapamycin inhibitors (sirolimus 
and everolimus). Above all, cyclosporine and tacrolimus 
are widely utilized because of their effect on humoral and 
cellular immunity, especially when they come in contact 
with T-helper cells during the early phase
3. A previous 
study reported that epidermal cyst occurred in 28% of 67 
patients receiving cyclosporine after renal transplantation. 
Koranda et al.
6 reported that no epidermal cyst was found 
in 200 patients undergoing renal transplantation who 
were not administered cyclosporine. Tacrolimus is in the 
same group as cyclosporine and is structurally different 
from cyclosporine, but has a similar mechanism of action. 
As per the literature survey, there have been few reports 
on occurrence of epidermal cysts after administration of 
tacrolimus. Some of the investigators have demonstrated 
that cyclosporine promotes keratinization, resulting in hair 
follicle occlusion and causing epidermoid cysts
2. We can 
postulate that tacrolimus might elicit a similar reaction as 
cyclosporine. It has been indicated that dendritic epider-
mal T cells secrete keratinocyte growth factor; thereby 
promoting the proliferation of keratinocytes
7. Tacrolimus 
may affect T cells by influencing the manifestation of 
keratinocytes so that they can act on the occurrence of 
mucocutaneous diseases, such as epidermal cysts. It is 
unclear whether HPV is truly an etiological factor or just a 
chance association. Recently, HPV type 57 and 60 DNAs 
have been detected in palmoplantar epidermal cysts. It is 
considered that tacrolimus induced immune suppression 
may influence HPV infection. Lee et al.
8 have shown that 
HPV can be detected in nonpalmoplantar skin lesions. In 
our case, it seems likely that HPV infection may be 
associated with the skin lesions although HPV immu-
nostain was not detected. Steroid-induced acneiform 
eruption may be attributed to administration of a high 
dose of steroid. However, the clinical and histological 
findings established a diagnosis of multiple epidermal 
cysts rather than acneiform eruption. Our patient received 
a high dose of tacrolimus 3 years ago, which was then 
gradually decreased. Thereafter, the patient continued to 
take it at a maintenance dose. In our case, the epidermal 
cyst seemed to occur due to a low dose of tacrolimus. 
Although epidermal cysts related to cyclosporine usually 
occur within 3 or 4 months of the initial treatment, in our 
case, the cysts occurred at an unusually late rate
2,3. This 
may be due to the characteristics of tacrolimus, which 
shows fewer side effects at a relatively low concent-
ration
4,9. Tacrolimus has received much attention not only 
in terms of post-transplantation immune suppression, but 
also in dermatologic treatment, exhibiting outstanding 
efficacy. In our report, we have presented a very rare side 
effect of tacrolimus.IS Ahn, et al
S184 Ann Dermatol
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